Chemical Properties:
Package: Fluorinated Bottle, 25kg/Barrel, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Febuxostat Related Intermediates: Febuxostat CAS 144060-53-7 Ethyl 2-Chloroacetoacetate CAS 609-15-4 4-Hydroxythiobenzamide CAS 25984-63-8 Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3 Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7 Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2 Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4 Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5| Item | Specifications |
| Appearance | Colorless to Light Yellow Clear Liquid |
| Purity / Analysis Method | >99.0% (GC) |
| 1 H NMR Spectrum | Consistent With Structure |
| Total Impurities | <1.00% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Febuxostat (CAS: 144060-53-7) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Ethyl 2-Chloroacetoacetate |
| Synonyms | 2-Chloroacetoacetic Acid Ethyl Ester; Ethyl 2-Chloro-3-Oxobutyrate |
| CAS Number | 609-15-4 |
| CAT Number | RF-PI1854 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C6H9ClO3 |
| Molecular Weight | 164.59 |
| Melting Point | -80℃ |
| Boiling Point | 107℃/14 mmHg (lit.) |
| Density | 1.19 g/mL at 25℃(lit.) |
| Refractive Index | n20/D 1.441 (lit.) |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Ethyl 2-Chloroacetoacetate (CAS: 609-15-4) is an important intermediate of Febuxostat (CAS: 144060-53-7). Febuxostat is a xanthine oxidase inhibitor, clinically used to treat hyperuricemia (gout). It is a new and highly effective selective inhibitor of non-purine xanthine oxidase. Xanthine oxidase is the key enzyme to promote uric acid production. Febuxosutan can reduce the uric acid level in the blood of patients with hyperuricemia and gout. Clinical studies have shown that the drug is safe and effective. The drug is metabolized through the liver and does not rely on renal excretion.
